CADTH has introduced a new type of recommendation. Time-limited drug reimbursement recommendations are a new recommendation category that will aim to help provide earlier access to promising new treatments that target the unmet needs of people in Canada living with severe, rare, or debilitating illnesses.

CADTH is pleased to announce the election of 3 new members to the CADTH Board of Directors.

“On behalf of the Board, I am pleased to welcome Louise Taylor Green, Dr. Jeffrey Tyberg, and Robert Shaffer as directors," said David Agnew, Board Chair. "Each of these remarkable individuals brings unique expertise, experience, and perspective to the board and we are delighted that they’ve joined us."

The international collaboration between 6 health technology assessment (HTA) bodies from across the UK, Australia, and Canada welcomes 2 further HTA bodies.

The addition of the Institut national d’excellence en santé et en services sociaux (INESSS) (Quebec) and Pharmac (New Zealand) to the collaboration will see more than 134 million people benefit from the group’s work.

The group, established in 2021, now includes:

CADTH is establishing an industry task force that will build upon the recently released Guidance for Reporting Real-World Evidence to provide advice on the use of industry-generated real-world data (RWD) in its Post-Market Drug Evaluation (PMDE) Program. We are inviting industry representatives to apply to be a part of this task force.